Colorectal cancer is a major cause of morbidity and mortality accounting for an estimated
550,000 deaths annually worldwide. Colonic neoplasia develops in a stepwise fashion …

Epidemiological studies suggest that aspirin and other nonsteroidal anti-inflammatory drugs
(NSAIDs) reduce the incidence of and mortality from colorectal, gastric, and esophageal …

Abstract Cyclooxygenase2 (COX-2), an inducible prostaglandin G/H synthase, is
overexpressed in several human cancers. Here, the potential utility of selective COX-2 …

Metabolites of arachidonic acid participate in normal growth responses and in aberrant
cellular growth and proliferation, including carcinogenesis. The key step in the conversion of …

COX-2 is upregulated at an early stage in colorectal carcinogenesis and generates
prostaglandins, which promote cancer cell proliferation, impair apoptosis and enhance …

Cyclooxygenase (COX), a key enzyme in the prostanoid biosynthetic pathway, has received
considerable attention due to its role in human cancers. Observational and randomized …

Aspirin has been used to control pain and inflammation for over a century. Epidemiological
studies first associated a decreased incidence of colorectal cancer with the long-term use of …

Clinical and animal studies indicate a role for cyclooxygenase-2 (COX-2) and the epidermal
growth factor receptor (EGFR) in the development and progression of intestinal polyps and …

Inhibitors of the inducible cyclooxygenase (COX‐2) have emerged as a promising new class
of drugs that may be useful for the prevention of colorectal cancer. Experimental evidence to …

Cyclooxygenase-2 (COX-2) is an inducible enzyme which triggers the biosynthesis of
prostaglandins. COX-2 is activated in response to inflammatory stimuli and is one of the …